Development and evaluation of Inhalable particdes Containing kanamycin monosulhate and pyrazinoic acid for the treatment of drug resistant tuberculosis.

Abstract

Tuberculosis (TB) remains a major health problem and a prime cause of global patient mortality throughout the world. Even after 90 years of vaccination and 60 years of advanced chemotherapy development, we are far away from eradicating the disease. All member states of the WHO and the UN pledged to eradicate TB by 2030 by reducing all TB deaths by 90% in the 2014 World Health Assembly. In developing nations and settings with limited resources, TB poses further challenges.